Phase 3 Readout

Phase 3 Topline: A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003

Indication
Thyroid Eye Disease

Other upcoming events for VRDN

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
Phase 3 ReadoutPhase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil
Phase 3 ReadoutPhase 3 Topline: REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 — VRDN Phase 3 Readout | BioSniper